Patients with metastatic urothelial carcinoma who achieve a favorable response to first-line systemic therapy face emerging clinical questions regarding the role of interval local consolidative therapy.
Evolving Treatment Standards in Metastatic Urothelial Carcinoma
Historically, patients diagnosed with metastatic urothelial carcinoma faced poor prognoses, with estimated five-year survival rates ranging between 5% and 15%, according to data cited from clinical studies. First-line treatments historically relied on cisplatin-based chemotherapy regimens such as gemcitabine and cisplatin or methotrexate, vinblastine, doxorubicin, and cisplatin. These standard protocols achieved a median overall survival of up to 15 months and complete response rates of roughly 12% over a median duration of approximately seven months.
The therapeutic landscape shifted with the introduction of novel first-line combination regimens, specifically enfortumab vedotin plus pembrolizumab and gemcitabine plus cisplatin combined with nivolumab. Clinical trials demonstrated that these combinations nearly doubled median overall survival compared to older cisplatin-based methods, extending survival to approximately 32 months. Furthermore, these regimens produced durable complete response rates of up to 30%. For instance, patients receiving gemcitabine plus cisplatin and nivolumab experienced a median duration of complete response reaching 37.1 months, while the duration of response for patients on enfortumab vedotin plus pembrolizumab has not yet been reached.
Indications for Deferred Local Therapy of the Primary Tumor
Despite receiving systemic therapy, more than 60% of patients with metastatic urothelial carcinoma retain their primary tumor. Data from the EV-302 trial show that 265 out of 442 patients in the treatment arm had not undergone a prior radical cystectomy or nephroureterectomy. Similarly, between 60.9% and 62.1% of patients treated with standard cisplatin-based chemotherapy retained their primary tumor.
In current clinical practice, deferred local therapy for the primary tumor generally serves two distinct purposes. First, palliative local therapy addresses persistent symptoms such as hematuria, hydronephrosis, urinary obstruction, dysuria, and pain that cannot be managed through less invasive interventions. Second, consolidative local therapy is evaluated when patients achieve a durable complete response at metastatic lesions while the primary tumor persists or demonstrates isolated progression.
Patients presenting with lymph node-only disease represent a particularly favorable subgroup regarding therapy response. Clinical evaluations documented objective response rates ranging from 77.5% in the EV-302 study to 81.5% in the CheckMate 901 trial, alongside complete response rates of 63% among patients treated with gemcitabine, cisplatin, and nivolumab.
These high response rates prompt clinicians to investigate whether interval local consolidative therapy of the primary tumor can eradicate remaining disease in patients who achieve sustained complete responses at metastatic sites, potentially allowing them to discontinue systemic treatment. This approach mirrors developments in metastatic renal cell carcinoma, where patients showing significant partial responses to immune checkpoint inhibitors are increasingly considered for deferred cytoreductive nephrectomy.